Jun. 22 at 2:50 PM
$NMRA The KOASTAL failure was brutal. No sugarcoating it.
But it did not kill NMRA.
Navacaprant is dead, but the company still has cash runway into Q3 2027, cut costs by reducing workforce, and now pivots fully to 3 remaining shots on goal: 511, 898, and 215.
And analysts are not walking away. Targets were cut, yes but several firms are still maintaining Buy/Outperform ratings with updated targets in the
$4–
$7 range after removing KOASTAL from the model.
That tells you the market may have over-punished this to the
$0.80s and why we recaptured alot of the the drop so quickly.
Now the story is simple: pipeline reset + cash runway + upcoming catalysts.
511 = Alzheimer’s agitation
898 = schizophrenia
215 = cardiometabolic/obesity
KOASTAL failed. NMRA didn’t.
From around
$1.50, any credible positive update on the remaining pipeline can re-rate this fast. NFA.
